SCHEMBL2572671

SCHEMBL2572671

CCCN(C)C(=O)c1cnc(-c2cn(CC3CCOCC3)c(C(C)(C)C)n2)s1

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 16/20 0.37
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
CNR1 P21554 3/20 0.33
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2564266 0.89 CNR2 (0.36) CNR2CNR1KCNH2
SCHEMBL2571965 0.81 CNR2 (0.36) CNR2RAB9ANPC1CNR1
SCHEMBL2564306 0.77 CNR2 (0.39) CNR2CNR1KCNH2
SCHEMBL2568616 0.75 CNR1 (0.40) CNR2RAB9ANPC1CNR1KCNH2
SCHEMBL2571681 0.75 CNR2 (0.38) CNR2CNR1KCNH2
SCHEMBL3418534 0.74 CNR1 (0.40) CNR2CNR1KCNH2
SCHEMBL2571933 0.74 CNR2 (0.39) CNR2RAB9ANPC1CNR1KCNH2
SCHEMBL2570054 0.74 CNR2 (0.38) CNR2CNR1KCNH2
SCHEMBL2567304 0.73 CNR2 (0.37) CNR2CNR1KCNH2
SCHEMBL2570734 0.73 CNR2 (0.38) CNR2CNR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289502-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-15 US disclosed
US-8273738-B2 Imidazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-09-25 US disclosed
EP-2090570-B1 IMIDAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2011-11-09 EP disclosed
US-20100152178-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
EP-2090570-A1 IMIDAZOLE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289502-A1 IMIDAZOLE DERIVATIVES CNR1, CNR2, ARRB1 CNR2 2/4885RAB9A 1616/4885NPC1 543/4885
US-20100152178-A1 IMIDAZOLE DERIVATIVES CNR1, CNR2, ARRB1 CNR2 2/4885RAB9A 1616/4885NPC1 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.